Forward Pharma A S
Forward Pharma A/S was a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The company completed a voluntary solvent liquidation in 2025.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Forward Pharma A S
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Forward Pharma A S
2 distinct titles indexed · top 2 shown.
- 1associate
- 1sales rep
Sign up to unlock all 2 contacts at Forward Pharma A S
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Forward Pharma A S
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.